The next generation of hormonal therapies for prostate cancer

Beyond abiraterone acetate and MDV3100 and even TAK-700, a new generation of treatments for hormonally driven cancers like prostate cancer (and breast cancer) is being explored by start-up companies like Aragon Pharmaceuticals. … READ MORE …